Latest Putamen Stories
SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it has closed its Series D preferred financing in the amount of $11.5 million.
An international collaboration led by academics at the University of Sheffield, has shed new light into ParkinsonÂ´s disease, which could help with the development of cures or treatments in the future.
SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients.
SAN DIEGO, June 22 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120.
SAN DIEGO, April 28 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients.
Integrated functional network could explain some mysteries of Parkinson's and dystonia
Researchers can predict your performance on a video game simply by measuring the volume of specific structures in your brain, a multi-institutional team reports this week.
SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease.
-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease.
- a meat pie that is usually eaten at Christmas in Quebec